ONCY pelareorep + PARP inhibitors = enhanced sensitizationNovember 2023 - Talazoparib, a clinical poly(ADP)-ribose polymerase 1 (PARP-1) inhibitor, is found to cause profound sensitisation to RT3D (reovirus/pelareorep)
Researchers found 100% tumour control and protection from subsequent tumour rechallenge with the combination regimen.
Taken together, these data provide a clear line of sight to clinical translation of combined regimens of PARP inhibition or ds-RNA agonism, with either viral or non-viral agents, in tumour types beyond the relatively narrow confines of current licensed indications for PARP inhibition
https://www.biorxiv.org/content/biorxiv/early/2023/12/22/2023.12.21.572541.full.pdf